好用的打印机驱动合集
打印机驱动共有6218款软件
Copyright &
PC6下载().All Rights Reserved
备案编号:湘ICP备号-10
湘网文 (-053号 增值电信业务经营许可证： 湘B2-【激光打印机FDA费用？】价格_厂家_图片 -Hc360慧聪网
您是不是在找：
买家还在看：
商品数量：
广东省&深圳市
手机访问店铺
供应激光打印机FDA费用？
卖家承诺&10天发货
买家正在看
相关商品推荐
&7.00/盒
商家等级：
所在地区：
广东省 深圳市
认证信息：
暂无炫铺分类
正在加载中........
慧聪网厂家深圳安博检测技术服务有限公司为您提供激光打印机FDA费用？的详细产品价格、产品图片等产品介绍信息，您可以直接联系厂家获取激光打印机FDA费用？的具体资料，联系时请说明是在慧聪网看到的。
热门商品推荐
我的浏览记录
其它商务服务相关资源
其它商务服务热门产品搜索
其它商务服务相关热门专题
您在慧聪网上采购商品属于商业贸易行为。以上所展示的信息由卖家自行提供，内容的真实性、准确性和合法性由发布卖家负责，请意识到互联网交易中的风险是客观存在的。推荐使用，保障您的交易安全！
按字母分类 ：
让慧聪网撮合专家为您解决采购难题
您采购的产品：
请输入采购产品
您的手机号码：
请输入手机号码
*采购产品：
请输入采购产品
*采购数量：
请输入采购数量
*采购截止日期：
请输入正确的手机号码
请输入验证码
*短信验证码：
<input id="valid_Code1" maxlength="6" placeholder="请输入验证码" name="VALIDCODE" class="codeInput" onkeyup="this.value=this.value.replace(/\D/g,'')" onkeypress="if(event.keyCode
57) event.returnValue =" type="text">
免费获取验证码
为了安全，请输入验证码，我们将优先处理您的需求！
请输入验证码
发送成功！
慧聪已收到您的需求，我们会尽快通知卖家联系您，同时会派出采购专员1对1为您提供服务，请您耐心等待！
电话：755- &&
联系人：邓娇&销售工程师
公司名称：深圳安博检测技术服务有限公司
请输入正确的手机号码
请输入验证码
*短信验证码：
免费获取验证码
为了安全，请输入验证码，我们将优先处理您的需求！
请输入验证码
每一份需求都会在24小时内得到行业多家优质供应商报价。
每一份需求的报价供应商工商信用资质都会经过专业人员检验，交易安全有保障。
免费咨询行业专家
免费咨询行业专家
服务主题：
筛选发货地
验证供应商真伪
提供其他优质供应商
采购数量：
用途描述：
成功加入采购单!
当前采购单共3种货品
成功加入采购单!
当前采购单共3种货品
不能购买自己发布的产品！
选中货品中含失效货品，无法完成下单，可能是：
1.货品库存不足
2.货品已过期，或被卖家删除
3.货品不支持在线交易
卖家暂时不在线，留下联系方式，卖家会主动联系您
*我要采购：
我的姓名：
留言内容：FDA CDRH FINAL GUIDANCES PRESENT NEW OPPORTUNITIES FOR SPONSORS
| LinkedIn
On April 13, 2015, the Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) issued two final guidance documents based on draft guidances issued last year:
Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval
Expedited Access for Premarket Approval and De Novo Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions
These two documents together represent the Agency’s current thinking on when data collection might be pushed from pre-approval to post-approval, with the second guidance focused on devices where there is a significant unmet medical need. The following is a summary of the information provided and recommendations for Sponsors looking to take advantage of opportunities to achieve earlier and less expensive medical device approval.
The first guidance does not appear to introduce any novel ideas, but rather reflects how CDRH has been utilizing postmarket data collection in recent years. Multiple examples are provided to describe types of data or situations where postmarket data collection is appropriate.
This guidance includes a brief discussion of the use of data collected outside the US, which may indicate increased flexibility in the type of data needed to establish safety and effectiveness of medical devices. The guidance describes the possibility of obtaining approval based on “long-term outside the US (OUS) clinical performance data” that is then either supplemented by&limited&clinical data collection from US patients prior to approval or US data collected&post-approval. Sponsors who have tried this approach in the past should re-engage with their review branch in order to see if OUS data can be used to limit the US data development program. CDRH recommends that Sponsors submit a Pre-Submission (Pre-Sub) outlining and justifying the proposal for pre- and post-approval data collection.
The second guidance represents a significant opportunity for Sponsors to leverage a new CDRH program to gain earlier approval for their device or device modification. In this final guidance, CDRH introduces the&Expedited Access Pathway (EAP)&that is specifically for&devices that address “unmet medical needs for life threatening or irreversibly debilitating diseases or conditions.” If a device is accepted in this pathway, the benefits appear to be significant, including:
More interactive review from FDA during both the IDE and PMA processes
Greater participation of Agency management
Case manager involvement where appropriate
Priority review
The opportunity to reduce manufacturing information requirements and push manufacturing inspections to after approval
However, the greatest potential benefit is the opportunity to work with the Agency on a mutually agreeable Data Development Plan, which identifies data to be collected premarket and postmarket. The goal of this plan is to identify data that can be gathered post-approval rather than pre-approval in order to significantly reduce the “time and cost from device development to FDA marketing decision.”
Inclusion in this program could lead to a product gaining approval one to two years earlier, with a significant proportion of the development costs pushed to the post-approval setting, where they can be balanced by commercial revenue. Because of this, Sponsors should be evaluating each development program to see if there is any opportunity to participate. To participate, the device or device modification has to fulfill these three criteria:
1.&Intended to treat or diagnose a life-threatening or irreversibly debilitating disease or condition
2. Meet&at least one&criteria for addressing an unmet need:
&&& a. No appropriate alternative treatment or means of diagnosis exists
&&& b. Breakthrough technology that provides a clinically meaningful advantage over existing legally marketed technology
&&& c. Clinically meaningful advantages over existing legally marketed alternatives (may include superiority over current treatments for effects on serious outcomes, substantially less risk, addressing a known and important shortcoming, or ability to provide clinical benefit to patients unable to tolerate current treatments)
&&& d. Availability of device is in the best interest of patients (e.g., addresses an unmet medical need)
3. Sponsor submits an acceptable draft Data Development Plan
One open question with this program is how CDRH will handle Advisory Committee meetings (referred to as Panel meetings for medical devices). Devices that qualify for this program will&almost certainly meet the criteria for a Panel meeting, yet Sponsors will not have generated the level of data that panelists are accustomed to seeing. The guidance is silent on this consideration, except to note that Panels can be used to evaluate data collected after approval for implications to labeling or the assessment of safety and effectiveness. Panels are currently used for this process, so this does not appear to be a unique feature of this program.
As an example of how this program could lead to earlier approval, consider a device that would typically require two years of clinical data before PMA submission. If the Sponsor can justify the approach, CDRH could accept the PMA for review with only six months of data while data collection continues through two years. Sponsors may also be able to better leverage OUS data and push collection of US data to the post-approval setting. Finally, CDRH may be more open to the use of surrogate endpoints or patient reported outcomes as the primary measures of effectiveness if there is a data-driven justification for doing so.
As with the first guidance, the second guidance recommends that interested Sponsors submit a Pre-Sub meeting request, including a detailed Data Development Plan. CDRH commits to providing feedback within 30 days on whether or not to grant EAP designation.
At this point, there does not appear to be a downside to participation in the EAP in fact, Sponsors should move quickly to submit proposals to participate as there are limited resources within CDRH to support this program. If your device is one that seems to be in the gray area – it may qualify, but it is not clear – begin a discussion with your review branch in order to assess participation criteria for your specific device type. Even if current projects don’t qualify, future projects should be continually assessed, as the program is intended to be ongoing if successful. Also, if accepted, Sponsors should be sure to have internal accelerated review processes so that they are able to match their reviewers’ attention and urgency. For smaller companies, this is not likely to be an obstacle, but could be an important consideration for larger companies with more rigid management review requirements.
The release of these two final guidance documents demonstrate CDRH’s current focus on their mission to provide patients and providers “timely and continued access to safe and effective and high quality medical devices.” Even an informal discussion with CDRH could provide insight into important opportunities for Sponsors to accelerate time to approval, while reducing costs pre-approval.
Read more 3D Communications Insight Blog Posts: &
Follow us on Twitter
&& && & and&&
Amy Tezel,&PhD, combines her extensive scientific background, regulatory experience across the entire FDA approval process, and an ability to communicate effectively to prepare clients for success. Amy’s experience in medical devices spans from pre-IDE, IDE, and PMA&preparations to FDA advisory committee meetings and post-approval commitment negotiations. Connect with Amy on&.Looking for more of the latest headlines on LinkedIn?}